Pharmaceuticals, Biotechnology and Life Sciences
Merck has received positive EU CHMP opinion for two new regimens of Keytruda (pembrolizumab) as first-line ttreatment for metastatic or…
Merck’s trial of Keytruda plus chemotherapy, followed by adjuvant Keytruda as monotherapy, which was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the neoadjuvant treatment of patients with high-risk, early-stage TNBC plus chemotherapy, resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy.
Noxxon will present latest Clinical data from phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress on Monday at 09.00 A.M., which shows that the combination of NOX-A12 and pembrolizumab induced an immune response, stable disease in 25% of patients and prolonged time on treatment vs. prior therapy for 35% of patients.
“The results of this Keytruda plus Lenvima study are a welcome development in the treatment of women with advanced endometrial cancer, a patient group with an unmet medical need,” said Dr. Vicky Makker, principal investigator and medical oncologist, Memorial Sloan Kettering Cancer Center.
Keytruda/lenvima combination treatment has been approved for certain patients with advanced endometrial carcinoma which isn’t Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR)
BerGenBio will have two presentations to highlight its Phase II clinical trial with bemcentinib and Merck’s anti-PD-1 therapy Keytruda in patients with advanced non-small cell lung cancer (NSCLC), which showed promising clinical activity overall.
Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment KENILWORTH, N.J.…
Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types
Keytruda’s market potential in this indication remains limited due to its approval for primary mediastinal B-cell lymphoma (PMBCL), which only accounts for a small percentage of non-Hodgkin’s lymphoma (NHL) patients.
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.